Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics.

@article{Kawabe2015MetabolicSA,
  title={Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics.},
  author={Kentaro Kawabe and Shinichiro Ochi and Yuta Yoshino and Yoko Mori and Hiroshi Onuma and Haruhiko Osawa and Yoshiki Hosoda and Shu-Ichi Ueno},
  journal={Therapeutic advances in psychopharmacology},
  year={2015},
  volume={5 5},
  pages={
          271-7
        }
}
BACKGROUND Common adverse effects of atypical antipsychotic treatments for schizophrenia are weight gain and lipid metabolism abnormality. We aimed to identify the signs of metabolic problems with continuous atypical antipsychotic treatment for schizophrenia over a 2-year period. METHODS The participants were 68 schizophrenic patients (29 males, 39 females; ages 53.4 ± 13.5 years old). Changes in carbohydrate metabolism and changes in physical characteristics were studied over a 2-year period… CONTINUE READING
BETA
1
Twitter Mention

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Dose equivalence of psychotropic drugs. Part XXI: dose equivalence of novel antipsychotics: blonanserin

A. Inagaki, T. Inada
  • Jap J Clin Psychopharmacol
  • 2008
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

D. Örey, F Richter
  • Lancet
  • 2013

metabolic syndrome: prevalence and the association with brachial-ankle pulse wave velocity in Japanese male workers

H. Onuma, Y. Tabara, +3 authors W Nishida
  • J Occup Health
  • 2010
VIEW 1 EXCERPT